 The abstract states that a new quantitative systems pharmacology model has been developed to account for differences between patients in a phase i clinical trial. It suggests that the drug may be more effective against tumours in patients with slower growing cancer or those with higher levels of T cells. This article was authored by Monica Isuzilo, Kai Chung Lee, Kapil Gadka, and others.